Icon Plc (NASDAQ:ICLR – Get Free Report) CEO Barry Balfe sold 5,175 shares of the business’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $206.66, for a total value of $1,069,465.50. Following the transaction, the chief executive officer owned 9,291 shares in the company, valued at approximately $1,920,078.06. This represents a 35.77% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Barry Edward Balfe also recently made the following trade(s):
- On Monday, August 10th, Barry Balfe sold 382 shares of Icon stock. The shares were sold at an average price of $164.07, for a total value of $62,674.74.
Icon Price Performance
ICLR stock opened at $203.77 on Wednesday. The firm has a market cap of $15.60 billion, a P/E ratio of 35.07, a price-to-earnings-growth ratio of 11.53 and a beta of 1.19. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.32 and a current ratio of 1.32. Icon Plc has a 1 year low of $66.57 and a 1 year high of $219.04. The stock has a 50-day simple moving average of $173.23 and a 200-day simple moving average of $146.72.
Icon (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings results on Tuesday, October 27th. The medical research company reported $2.66 EPS for the quarter, topping the consensus estimate of $2.62 by $0.04. The firm had revenue of $2.02 billion for the quarter, compared to analyst estimates of $2.01 billion. Icon had a return on equity of 7.73% and a net margin of 5.45%. Icon’s revenue for the quarter was down .9% on a year-over-year basis. During the same period in the previous year, the company posted $3.31 EPS. On average, equities analysts predict that Icon Plc will post 9.57 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Icon
A number of institutional investors have recently made changes to their positions in ICLR. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Icon during the third quarter worth approximately $38,000. GAMMA Investing LLC increased its stake in shares of Icon by 21.4% in the second quarter. GAMMA Investing LLC now owns 391 shares of the medical research company’s stock worth $68,000 after buying an additional 69 shares during the last quarter. Fifth Third Bancorp raised its holdings in Icon by 1,062.0% in the first quarter. Fifth Third Bancorp now owns 918 shares of the medical research company’s stock valued at $102,000 after acquiring an additional 839 shares in the last quarter. Parkside Financial Bank & Trust raised its holdings in Icon by 120.0% in the second quarter. Parkside Financial Bank & Trust now owns 616 shares of the medical research company’s stock valued at $107,000 after acquiring an additional 336 shares in the last quarter. Finally, Bessemer Group Inc. boosted its stake in Icon by 804.8% during the 1st quarter. Bessemer Group Inc. now owns 1,312 shares of the medical research company’s stock valued at $145,000 after acquiring an additional 1,167 shares during the last quarter. 95.61% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
A number of research analysts have recently commented on the stock. Weiss Ratings raised shares of Icon from a “sell (d)” rating to a “sell (d+)” rating in a research report on Wednesday, October 28th. William Blair raised shares of Icon to a “strong-buy” rating in a report on Thursday, July 30th. Evercore reaffirmed an “outperform” rating and set a $240.00 price target on shares of Icon in a research note on Wednesday, October 28th. Barclays boosted their price objective on shares of Icon from $175.00 to $230.00 and gave the stock an “equal weight” rating in a report on Thursday, October 29th. Finally, Bank of America raised shares of Icon from an “underperform” rating to a “neutral” rating and set a $185.00 price objective for the company in a research report on Friday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Icon has an average rating of “Moderate Buy” and a consensus price target of $213.76.
View Our Latest Research Report on Icon
Icon Company Profile
ICON plc is a global contract research organization that provides outsourced development services to pharmaceutical, biotechnology and medical device companies. The company supports clinical research programs from early development through late-stage trials, regulatory submission and post-marketing activities.
Its services include clinical trial management, medical and regulatory consulting, biostatistics, data management, pharmacovigilance, laboratory services and real-world evidence solutions.
Read More
- Five stocks we like better than Icon
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
- Franklin Templeton’s New ETFs Turn Stock Dividends Into Bitcoin—What’s the Catch?
- Apple’s Earnings Beat Comes With a Catch for Investors Heading Into the Holidays
- Palantir’s $2.3 Billion Quarter Puts Its Premium Valuation to the Test
Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.
